



## Rhinovirus Infections 2.0

Guest Editor:

**Prof. Dr. Gary McLean**

1. Molecular Immunology, School of Human Sciences, London Metropolitan University, London, UK

2. Faculty of Medicine, National Heart & Lung Institute, Imperial College London, London, UK

Deadline for manuscript submissions:

**closed (30 September 2022)**

### Message from the Guest Editor

Rhinoviruses are small nonenveloped RNA viruses belonging to the family Picornaviridae, and are recognized as the major cause of common colds and acute exacerbations of asthma and chronic obstructive pulmonary disorder (COPD) in humans. These viruses are extremely antigenically diverse in structure, with approximately 160 distinct serotypes/strains grouped into three types, A, B, and C, with further distinctions based on entry receptor requirements where three different cell-surface molecules have been described. Immunity to rhinoviruses is generally considered to be serotype-specific. Despite intensive studies since their discovery in the 1960s, no effective antiviral or vaccine has been invented to combat these ubiquitous pathogens.

In this updated Special Issue of *Viruses*, we aim to gather research and review papers that contribute to an improved understanding of rhinovirus structure, classification, infections, epidemiology, and immunopathology, or that report the development of vaccines or antiviral agents. Studies that address rhinovirus infections epidemiology during the COVID-19 pandemic are particularly encouraged.





an Open Access Journal by MDPI

## Editor-in-Chief

### Dr. Eric O. Freed

Director, HIV Dynamics and  
Replication Program, Center for  
Cancer Research, National  
Cancer Institute, Frederick, MD  
21702-1201, USA

## Message from the Editor-in-Chief

*Viruses* (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **MEDLINE**, **PMC**, **Embase**, **PubAg**, **AGRIS**, and **other databases**.

**Journal Rank:** JCR - Q2 (*Virology*) / CiteScore - Q1 (*Infectious Diseases*)

## Contact Us

*Viruses* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/viruses](http://mdpi.com/journal/viruses)  
[viruses@mdpi.com](mailto:viruses@mdpi.com)  
[X@VirusesMDPI](https://twitter.com/VirusesMDPI)